A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial Infarction
Melchior Seyfarth, MD*, ,*,
Dirk Sibbing, MD*,
Iris Bauer, MS*,
Georg Fröhlich, MD,
Lorenz Bott-Flügel, MD,
Robert Byrne, MB, MRCPI*,
Josef Dirschinger, MD,
Adnan Kastrati, MD* and
Albert Schömig, MD*,
* Deutsches Herzzentrum München, Technische Universität, Munich, Germany
1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Time Course of CPI Serum Lactate, and Hemolysis
(A) Time course of the modified cardiac power index (CPI) after implantation of Impella LP2.5 or intra-aortic balloon pump. For Impella patients, total CPI is shown as the sum of CPI attributable to the work of the left ventricle (LV) (CPILV; red bars) and of the device (CPIImpella, black bars). (B) Time course of serum lactate (mean ± SD). (C) Time course of free hemoglobin (median and interquartile range). *p < 0.05 between treatment groups at the specific time points.
|
|
View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Organ Dysfunction Scores and Survival Curve
(A) Multiple Organ Dysfunction Score (MODS). (B) Sepsis-related Organ Failure Assessment (SOFA). Scores are shown at baseline and 30 days. Values are mean ± SD. *p < 0.01 between baseline and 30 days for each score and each treatment group. (C) Overall 30-day survival curves for Impella patients versus intra-aortic balloon pump patients.
|
|
|
